Benchmark began coverage on shares of Tilray (NASDAQ:TLRY) in a research note published on Tuesday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $200.00 price objective on the stock.
Other equities analysts have also issued reports about the company. Roth Capital started coverage on Tilray in a research note on Tuesday, August 14th. They issued a buy rating and a $35.00 price objective on the stock. Northland Securities lowered Tilray from an outperform rating to a market perform rating in a research note on Thursday, September 6th. Finally, Cowen lifted their price objective on Tilray from $62.00 to $172.00 and gave the company an outperform rating in a research note on Tuesday, October 9th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. Tilray presently has a consensus rating of Hold and an average target price of $135.67.
NASDAQ TLRY opened at $152.53 on Tuesday. Tilray has a 1-year low of $20.10 and a 1-year high of $300.00. The company has a debt-to-equity ratio of 0.24, a quick ratio of 0.51 and a current ratio of 0.62.
In related news, CRO Edward Wood Pastorius, Jr. purchased 14,705 shares of Tilray stock in a transaction that occurred on Monday, July 23rd. The shares were purchased at an average cost of $17.00 per share, with a total value of $249,985.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Brendan Kennedy purchased 14,706 shares of Tilray stock in a transaction that occurred on Monday, July 23rd. The shares were bought at an average cost of $17.00 per share, for a total transaction of $250,002.00. The disclosure for this purchase can be found here.
An institutional investor recently bought a new position in Tilray stock. Bank of Montreal Can purchased a new position in shares of Tilray Inc (NASDAQ:TLRY) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 17,179 shares of the company’s stock, valued at approximately $2,467,000.
Tilray Company Profile
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc was incorporated in 2018 and is headquartered in Nanaimo, Canada.
See Also: Why do earnings reports matter?
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.